Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma
Abstract
Functionalized fullerenes represent a new class of photosensitizer (PS) that is being investigated for photodynamic therapy (PDT) of various diseases, including cancer. We tested the hypothesis that fullerenes could be used to mediate PDT of intraperitoneal (IP) carcinomatosis in a mouse model. In humans this form of cancer responds poorly to standard treatment and manifests as a thin covering of tumor nodules on intestines and on other abdominal organs. We used a colon adenocarcinoma cell line (CT26) stably expressing luciferase to allow monitoring of IP tumor burden in BALB/c mice by noninvasive real-time optical imaging using a sensitive low-light camera. IP injection of a preparation of N-methylpyrrolidinium-fullerene formulated in Cremophor-EL micelles, followed by white-light illumination delivered through the peritoneal wall (after creation of a skin flap), produced a statistically significant reduction in bioluminescence and a survival advantage in mice.
Additional Information
© 2011 Elsevier Inc. Received 17 December 2010; accepted 17 April 2011. The authors are grateful to QLT Inc, Vancouver, Canada for the gift of Photofrin. Conflict of Interest Statement: At the time of the research Tim Wharton was an employee of Lynntech Inc. Pawel Mroz, Tim Wharton and Michael R. Hamblin are inventors on a patent describing the use of fullerenes as photosensitizers for PDT that has been licensed by Lynntech. The Hamblin laboratory has received funding in Phase 1 and 2 SBIR grants awarded to Lynntech. This work was supported by US NIH grants R43AI68400 to Lynntech Inc and R01AI050875 to M.R.H. and by the US Air Force Medical Free Electron Laser Program (FA9550-04-1-0079). P.M. was partly supported by a Genzyme-Partners Translational Research Grant and NIH Training Grant. T. D. was supported by the Bullock Wellman Postdoctoral Fellowship and an Airlift Research Foundation grant (grant #109421). The authors are also grateful to Dr. Andrew Kung from the Department of Pediatric Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, for providing CT26Luc cell line.Additional details
- Eprint ID
- 28665
- Resolver ID
- CaltechAUTHORS:20120105-091152636
- SBIR
- R43 AI68400
- NIH
- R01 AI050875
- NIH
- FA9550-04-1-0079
- Air Force Medical Free Electron Laser Program
- Genzyme-Partners Translational Research Grant
- NIH Training Grant
- Bullock Wellman Postdoctoral Fellowship
- 109421
- Airlift Research Foundation
- Created
-
2012-01-05Created from EPrint's datestamp field
- Updated
-
2021-11-09Created from EPrint's last_modified field